Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 24 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.17 Insider Own19.35% Shs Outstand36.34M Perf Week-2.72%
Market Cap26.20M Forward P/E- EPS next Y-0.40 Insider Trans1.72% Shs Float29.35M Perf Month1.39%
Income-31.48M PEG- EPS next Q-0.14 Inst Own56.15% Short Float0.11% Perf Quarter2.99%
Sales0.00M P/S- EPS this Y49.00% Inst Trans44.24% Short Ratio0.95 Perf Half Y43.98%
Book/sh0.97 P/B0.74 EPS next Y22.55% ROA-77.74% Short Interest0.03M Perf Year-31.44%
Cash/sh1.02 P/C0.71 EPS next 5Y- ROE-84.92% 52W Range0.38 - 1.15 Perf YTD-12.39%
Dividend Est.- P/FCF- EPS past 5Y51.36% ROI-89.13% 52W High-37.38% Beta0.47
Dividend TTM- Quick Ratio10.45 Sales past 5Y-20.00% Gross Margin- 52W Low89.45% ATR (14)0.05
Dividend Ex-Date- Current Ratio10.45 EPS Y/Y TTM-47.67% Oper. Margin0.00% RSI (14)50.60 Volatility6.15% 7.36%
Employees9 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price2.88
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q30.40% Payout- Rel Volume0.41 Prev Close0.74
Sales Surprise- EPS Surprise100.00% Sales Q/Q- EarningsMar 18 AMC Avg Volume34.70K Price0.72
SMA20-0.03% SMA502.45% SMA2001.48% Trades Volume14,300 Change-2.53%
Date Action Analyst Rating Change Price Target Change
Apr-08-24Upgrade Ladenburg Thalmann Neutral → Buy $2.75
Sep-20-21Upgrade Chardan Capital Markets Sell → Buy $4 → $3.50
Sep-03-21Downgrade Truist Buy → Hold $4
Sep-03-21Downgrade Ladenburg Thalmann Buy → Neutral
Sep-03-21Downgrade Chardan Capital Markets Buy → Sell $105 → $4
Sep-03-21Downgrade B. Riley Securities Buy → Neutral $3
May-14-21Initiated B. Riley Securities Buy $73
Mar-26-21Initiated Citigroup Buy $75
Aug-28-20Upgrade Chardan Capital Markets Neutral → Buy $45
Aug-25-20Initiated Truist Buy $70
Mar-25-24 12:00PM
Mar-19-24 06:53AM
Mar-18-24 04:05PM
Dec-04-23 07:21AM
Dec-01-23 04:01PM
04:01PM Loading…
Nov-13-23 04:01PM
Sep-14-23 10:50AM
Sep-06-23 03:15PM
Aug-25-23 08:00AM
Aug-14-23 04:01PM
Aug-01-23 04:01PM
Jun-20-23 08:00AM
May-19-23 04:01PM
May-15-23 04:01PM
Mar-31-23 04:05PM
04:05PM Loading…
Jan-12-23 04:05PM
Nov-14-22 04:01PM
Aug-17-22 08:00AM
Aug-15-22 04:05PM
Jul-08-22 07:16AM
Jun-07-22 09:00AM
May-16-22 09:00AM
Dec-15-21 05:55AM
Sep-09-21 06:15PM
Sep-08-21 08:51AM
Sep-07-21 09:40PM
Sep-06-21 12:42PM
Sep-03-21 07:42PM
02:14PM Loading…
Sep-02-21 04:05PM
Aug-16-21 04:05PM
Aug-02-21 04:01PM
Jul-12-21 04:01PM
Jul-07-21 10:02AM
Jul-01-21 04:01PM
May-14-21 03:06AM
May-10-21 04:05PM
May-03-21 04:30PM
Mar-25-21 08:42AM
Mar-24-21 08:00AM
Mar-17-21 04:05PM
Feb-23-21 04:01PM
Feb-18-21 04:01PM
Feb-13-21 03:18AM
Feb-12-21 04:01PM
Dec-02-20 11:26PM
Nov-24-20 04:05PM
Nov-16-20 04:05PM
Nov-15-20 09:00AM
Nov-10-20 04:05PM
Nov-09-20 04:05PM
Nov-02-20 04:30PM
Oct-29-20 08:00AM
Oct-28-20 04:09PM
Oct-26-20 08:30AM
Sep-29-20 09:00AM
Sep-16-20 08:48AM
Sep-09-20 04:01PM
Aug-25-20 08:30AM
Aug-10-20 04:00PM
Aug-03-20 09:00AM
Jul-28-20 08:30AM
Jun-18-20 08:30AM
Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The firm's lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner in 2017 and is headquartered in Dallas, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Riley Antony ACHIEF FINANCIAL OFFICERApr 01 '24Option Exercise0.009,3750197,819Apr 02 06:32 PM
Wagner Paul A.SEE REMARKSApr 01 '24Option Exercise0.0031,25001,881,627Apr 02 06:31 PM
Riley Antony AChief Financial OfficerJan 01 '24Option Exercise0.009,3750192,285Jan 03 04:02 PM
Chen Hubert CSee remarksJan 01 '24Option Exercise0.007,500096,478Jan 03 04:04 PM
Wagner Paul A.See RemarksJan 01 '24Option Exercise0.0031,25001,854,486Jan 03 04:01 PM
Wagner Paul A.See RemarksDec 18 '23Buy0.7510,0007,5251,823,236Dec 20 10:56 AM
Wagner Paul A.See RemarksDec 14 '23Buy0.7210,0007,2001,813,236Dec 15 06:29 PM
Wagner Paul A.See RemarksDec 13 '23Buy0.7010,5207,3511,803,236Dec 15 06:29 PM
Wagner Paul A.See RemarksDec 12 '23Buy0.654,7763,0881,792,716Dec 12 07:30 PM
Wagner Paul A.See RemarksDec 11 '23Buy0.6525,00016,1881,787,940Dec 12 07:30 PM
Wagner Paul A.See RemarksDec 08 '23Buy0.6215,0009,3001,762,940Dec 08 07:20 PM
Wagner Paul A.See RemarksDec 07 '23Buy0.5836,20321,1681,747,940Dec 08 07:20 PM
Wagner Paul A.See RemarksNov 22 '23Buy0.434001721,711,737Nov 22 05:51 PM
Wagner Paul A.See RemarksNov 20 '23Buy0.446,9663,0481,711,337Nov 22 05:51 PM
Chen Hubert CSee remarksOct 01 '23Option Exercise0.007,500091,571Oct 03 04:29 PM
Wagner Paul A.See RemarksOct 01 '23Option Exercise0.0031,25001,706,824Oct 03 04:26 PM
Riley Antony AChief Financial OfficerOct 01 '23Option Exercise0.009,3750186,151Oct 03 04:27 PM
Riley Antony AChief Financial OfficerJul 01 '23Option Exercise0.009,375028,003Jul 05 04:06 PM
Wagner Paul A.See RemarksJul 01 '23Option Exercise0.0031,25001,430,503Jul 05 04:04 PM
Chen Hubert CSee remarksJul 01 '23Option Exercise0.007,500012,407Jul 05 04:08 PM